Document text
Principal Investigator: Kristina De Paris
Organization: UNIV OF NORTH CAROLINA CHAPEL HILL
Fiscal Year: 2024
Award: $195,770
Funding agency: National Institute of Allergy and Infectious Diseases
ABSTRACT
The SARS-CoV-2 pandemic has resulted in enormous loss of life and in long-lasting health sequalae in a subset
of convalescent patients. Little is known about the impact of SARS-CoV-2 infection on people with primary
immune deficiency diseases (PIDD). There is also a lack of guidelines regarding the inclusion of people with
PIDD in SARS-CoV-2 vaccination efforts.
Among PIDD, primary antibody deficiencies are most prevalent. X-linked agammaglobulinemia (XLA) is a genetic
disorder that is estimated to occur in 1 of 200,000 births and is caused by a mutation in Bruton tyrosine kinase
(BTK) that leads to an arrest in B cell development. Thus, XLA patients cannot mount antibody responses and
require lifelong therapy with gammaglobulin infusions to prevent infections. These infusions, however, do not
contain antibodies to the recently emerged SARS-CoV-2 virus leaving these patients vulnerable to COVID-19.
The currently approved SARS-CoV-2 vaccines are thought to mediate protection against infection through the
induction of neutralizing antibodies. However, all current SARS-CoV-2 vaccine candidates have the potential to
elicit humoral and T cell responses. Although T cell responses cannot protect against viral infection, anti-viral T
cell responses are critical in the control of virus replication and dissemination. In XLA patients, T cell responses
are considered to be normal. Thus, we hypothesize that the currently approved SARS-CoV-2 mRNA vaccines
will elicit persistent Spike protein-specific T cell responses with the potential to protect against disease against
the vaccine strain and variants of concerns. Support for our hypothesis is provided by data documenting that
XLA patients receiving the inactivated influenza vaccine can mount protective influenza-specific T cell responses
at a similar magnitude and quality as immunocompetent individuals. Aim 1 of the proposed studies will assess
magnitude, function, durability, and breadth of SARS-CoV-2 specific T cell responses in XLA patients prior to
and at week 1, week 3, 4 months and 1 year after vaccination and/or boost with one of the two approved SARS-
CoV-2 Spike protein mRNA vaccines. XLA patients, however, can encompass a broad spectrum of BTK
mutations. Some BTK mutations can inhibit Toll-like receptor signaling and other innate functions in monocytes
and dendritic cells. Both monocytes and dendritic cells are important in the priming and activation of antigen-
specific T cells. Therefore, Aim 2 of the proposed studies, will assess the function of monocytes and dendritic
cells in XLA participants and correlate these functional parameters to vaccine-induced T cell responses in the
same patient. To perform the studies, we will leverage well-established cohorts of XLA patients at Duke, UNC,
and USF. The results of our study are expected to inform health policies regarding the inclusion of XLA patients
in SARS-CoV-2 vaccination efforts and provide the foundation for larger studies with other PIDD populations.
Terms: <0-11 years old><2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><2019-nCoV variant><2019-nCoV variant forms><2019-nCoV variant strains><21+ years old><APC Vaccine><Activities of Daily Living><Activities of everyday life><Adult><Adult Human><Affect><Agammaglobulinaemia tyrosine kinase><Age><Antibodies><Antibody Response><Antigen-Presenting Cells><Antigens><Authorization><Authorization documentation><B blood cells><B cell><B cell progenitor kinase><B cells><B-Cell Development><B-Cells><B-Lymphocytes><B-cell><BNT 162b2><BNT162b2><Bacterial Infections><Birth><Blood monocyte><Bruton agammaglobulinemia><Bruton's Sex-Linked Agammaglobulinemia><Bruton's X-Linked Agammaglobulinemia><Bruton's tyrosine kinase><CD8 Cell><CD8 T cells><CD8 lymphocyte><CD8+ T cell><CD8+ T-Lymphocyte><CD8-Positive Lymphocytes><CD8-Positive T-Lymphocytes><COVID crisis><COVID epidemic><COVID pandemic><COVID-19><COVID-19 S protein><COVID-19 crisis><COVID-19 epidemic><COVID-19 era><COVID-19 global health crisis><COVID-19 global pandemic><COVID-19 health crisis><COVID-19 infection><COVID-19 pandemic><COVID-19 period><COVID-19 predisposition><COVID-19 public health crisis><COVID-19 spike><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 susceptibility><COVID-19 vaccination><COVID-19 vaccine><COVID-19 variant><COVID-19 variant forms><COVID-19 variant strains><COVID-19 virus><COVID-19 virus infection><COVID-19 vulnerability><COVID-19 years><COVID19 infection><COVID19 virus><CV-19><Cell Body><Cell Communication and Signaling><Cell Function><Cell Physiology><Cell Process><Cell Signaling><Cells><Cellular Function><Cellular Physiology><Cellular Process><Child><Child Youth><Children (0-21)><CoV-2><CoV2><Coronavirus Infectious Disease 2019><Coronavirus disease 2019 predisposition><Coronavirus disease 2019 susceptibility><Coronavirus disease 2019 vulnerability><Data><Deficiency Diseases><Dendritic Cells><Development><Disease><Disorder><Face><Foundations><Gamma globulin><Genetic Alteration><Genetic Change><Genetic Diseases><Genetic defect><Goals><Grippe><Guidelines><Health><Health Care Providers><Health Personnel><Health Policy><Healthcare Providers><Healthcare worker><Human><Immune><Immune response><Immunes><Immunization><Immunocompetent><Immunocompromised><Immunocompromised Host><Immunocompromised Patient><Immunodeficiency Disorder><Immunodeficiency Syndrome><Immunologic Deficiency Syndromes><Immunological Deficiency Syndromes><Immunological response><Immunosuppressed Host><Impairment><In Vitro><Individual><Infection><Infection prevention><Influenza><Influenza Vaccines><Infusion><Infusion procedures><Intracellular Communication and Signaling><Life><Ligands><Link><Lung damage><Lung infections><Marrow monocyte><Mature B-Cell><Mature B-Lymphocyte><Measures><Mediating><Memory><Messenger RNA><Modern Man><Mutation><Organ><Outcome><Participant><Parturition><Patients><Permission><Persons><Pfizer covid19 vaccine><Pfizer-BioNTech COVID-19 vaccine><Pfizer-BioNTech coronavirus disease 2019 vaccine><Pfizer/BioNTech vaccine><Play><Population><Predisposed to COVID-19><Predisposed to SARS-CoV-2><Predisposed to Severe acute respiratory syndrome coronavirus 2><Prevent infection><Primary Immunodeficiency><Production><Proteins><RNA immunization><RNA vaccination><RNA vaccine><RNA-based vaccine><Receptor Signaling><Role><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S><SARS-CoV-2 S protein><SARS-CoV-2 epidemic><SARS-CoV-2 global health crisis><SARS-CoV-2 global pandemic><SARS-CoV-2 infection><SARS-CoV-2 pandemic><SARS-CoV-2 predisposition><SARS-CoV-2 spike><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 susceptibility><SARS-CoV-2 vaccination><SARS-CoV-2 vaccine><SARS-CoV-2 variant><SARS-CoV-2 variant forms><SARS-CoV-2 variant strains><SARS-CoV-2 vulnerability><SARS-CoV2><SARS-CoV2 infection><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 epidemic><SARS-coronavirus-2 pandemic><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 epidemic><Severe Acute Respiratory Syndrome CoV 2 pandemic><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 epidemic><Severe acute respiratory syndrome coronavirus 2 infection><Severe acute respiratory syndrome coronavirus 2 pandemic><Severe acute respiratory syndrome coronavirus 2 predisposition><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 susceptibility><Severe acute respiratory syndrome coronavirus 2 vaccination><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome coronavirus 2 vulnerability><Severe acute respiratory syndrome related corona virus 2><Signal Transduction><Signal Transduction Systems><Signaling><Subcellular Process><T cell response><T-Cell Development><T-Cell Ontogeny><T-Cells><T-Lymphocyte><T-Lymphocyte Development><T8 Cells><T8 Lymphocytes><TLR protein><Toll-Like Receptor Family Gene><Toll-like receptors><United States><Vaccination><Vaccine Clinical Trial><Vaccines><Variant><Variation><Veiled Cells><Viral><Viral Diseases><Virus><Virus Activation><Virus Diseases><Virus Induction><Virus Replication><Vulnerable Populations><Wuhan coronavirus><X-Linked Agammaglobulinemia><accessory cell><adulthood><age group><ages><antigen-presenting cell vaccine><antigen-specific T cells><bacteria infection><bacterial disease><biological signal transduction><bpk protein><btk protein><cohort><congenital immune deficiency><congenital immunodeficiency><coronavirus disease 2019><coronavirus disease 2019 S protein><coronavirus disease 2019 crisis><coronavirus disease 2019 epidemic><coronavirus disease 2019 global health crisis><coronavirus disease 2019 global pandemic><coronavirus disease 2019 health crisis><coronavirus disease 2019 infection><coronavirus disease 2019 pandemic><coronavirus disease 2019 public health crisis><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccination><coronavirus disease 2019 vaccine><coronavirus disease 2019 variant><coronavirus disease 2019 variant forms><coronavirus disease 2019 variant strains><coronavirus disease 2019 virus><coronavirus disease crisis><coronavirus disease epidemic><coronavirus disease pandemic><coronavirus disease-19><coronavirus disease-19 global pandemic><coronavirus disease-19 pandemic><coronavirus disease-19 vaccine><coronavirus disease-19 virus><coronavirus infectious disease-19><cross reactivity><cytokine><daily living function><daily living functionality><deploy vaccines><developmental><distribute vaccines><faces><facial><flu vaccine><flu virus vaccine><functional ability><functional capacity><genetic condition><genetic disorder><genetic immune defect><genetic immune deficiency><genetic immunodeficiency><genome mutation><hCoV19><health care personnel><health care policy><health care worker><health provider><health workforce><healthcare personnel><healthcare policy><hesitant to vaccination><host response><immune competent><immune deficiency disorder><immune system response><immunogen><immunoresponse><immunosuppressed patient><inborn errors in immunity><inborn errors of immunity><inborn immunodeficiency><infected with COVID-19><infected with COVID19><infected with SARS-CoV-2><infected with SARS-CoV2><infected with coronavirus disease 2019><infected with severe acute respiratory syndrome coronavirus 2><infection recurrence><influenza virus vaccine><infusions><inherited immune defect><inherited immune deficiency><inherited immunodeficiency><kids><life-threatening COVID><life-threatening COVID-19><life-threatening SARS-CoV-2><life-threatening coronavirus disease><life-threatening coronavirus disease 2019><life-threatening severe acute respiratory syndrome coronavirus 2><lung injury><mRNA><mRNA immunization><mRNA vaccination><mRNA vaccine><mRNA-based vaccine><male><medical personnel><monocyte><nCoV vaccine><nCoV-19 vaccine><nCoV19 vaccine><nCoV2><neutralizing antibody><predisposed to Coronavirus disease 2019><prevent><preventing><primary immune defect><primary immune deficiency><pulmonary damage><pulmonary infections><pulmonary injury><pulmonary tissue damage><pulmonary tissue injury><recurrent infection><recurring infection><serious COVID><serious COVID-19><serious SARS-CoV-2><serious coronavirus disease><serious coronavirus disease 2019><serious severe acute respiratory syndrome coronavirus 2><severe COVID><severe COVID-19><severe COVID19><severe SARS-CoV-2><severe acute respiratory syndrome coronavirus 2 global health crisis><severe acute respiratory syndrome coronavirus 2 global pandemic><severe acute respiratory syndrome coronavirus 2 variant><severe acute respiratory syndrome coronavirus 2 variant forms><severe acute respiratory syndrome coronavirus 2 variant strains><severe coronavirus disease><severe coronavirus disease 19><severe coronavirus disease 2019><severe severe acute respiratory syndrome coronavirus 2><sex><social role><spike proteins on SARS-CoV-2><susceptible to COVID-19><susceptible to Coronavirus disease 2019><susceptible to SARS-CoV-2><susceptible to Severe acute respiratory syndrome coronavirus 2><thymus derived lymphocyte><treatment provider><vaccinate against COVID-19><vaccinate against SARS-CoV-2><vaccinate against coronavirus disease 2019><vaccinate against severe acute respiratory syndrome coronavirus 2><vaccination against COVID-19><vaccination against SARS-CoV-2><vaccination against Severe acute respiratory syndrome coronavirus 2><vaccination against coronavirus disease 2019><vaccination hesitancy><vaccine against 2019-nCov><vaccine against COVID-19><vaccine against SARS-CoV-2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine against flu><vaccine against influenza><vaccine candidate><vaccine candidates against SARS-CoV-2><vaccine deployment><vaccine distribution><vaccine for novel coronavirus><vaccine hesitancy><vaccine hesitant><vaccine roll-out><vaccine rollout><vaccines preventing COVID><vaccines to prevent COVID><variants of concern><viral activation><viral induction><viral infection><viral multiplication><viral replication><virus infection><virus multiplication><virus-induced disease><vulnerable group><vulnerable individual><vulnerable people><vulnerable to COVID-19><vulnerable to Coronavirus disease 2019><vulnerable to SARS-CoV-2><vulnerable to Severe acute respiratory syndrome coronavirus 2><youngster><γ globulin>